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Introduction
Chronic low-grade inflammation and activation of the innate 
immune system are closely involved in the pathobiochemical and 
immunopathogenesis of type 2 diabetes mellitus (DM2).1 Both 
acute and chronic hyperglycemias determine a pro-inflammatory 
state. A single hyperglycaemia-induced process of overproduction 
of reactive oxygen species (ROS) seems to be important in the 
activation of all of the other pathways involved in the pathogene-
sis of diabetic inflammatory complications.2 Additionally, acute-
phase circulating inflammatory responses, of which interleukin 
6 (IL-6) appears to be the major cytokine mediator, are strong 
predictors of the development of DM2, and it is believed that 
cytokine production may be mediated by ROS.1 Hyperglycaemia 
produces alterations to various signalling pathways resulting in 
the modulation of cellular reactivity.3-5 In this context, cAMP is 
an important second messenger of cellular activation. The pres-
ence of cAMP-elevating agents has been shown to inhibit IL-2 
and gamma-interferon (IFNγ), but not as to IL-4 and IL-5, in 
Jurkat cells.6 Moreover, cAMP potentiates IL-6 production in 
neuronal cells and inhibits such production in adipocytes.7,8 The 
intracellular level of cAMP is elevated following activation of 
adenyl cyclase by prostaglandin E2 (PGE2).9 Interestingly, PGE2 
is produced by inflammatory cells,9 and the levels of PGE2 are 
significantly elevated in a diabetic   population with nephropathy 
and retinopathy.10,11 In diabetic rats, the level of PGE2 is increased 
by hyperglycaemia.12
We have previously suggested that an increase in the level of 
cAMP inhibits ROS and NO production in granulocytes from 
healthy subjects, but activates their generation in cells from DM2 
patients.13 In the present study we have investigated the effect of a 
cAMP-elevating agent on ROS, IL-4, IL-6 and IFNγ production 
by peripheral blood mononuclear cells (PBMNC) from DM2 
patients  in  addition  to  evaluate  possible  correlations  between 
ROS generation and cytokine secretion by these cells.
Results
Patients.  Biochemical  parameters  of  type  2  diabetic  patients 
and healthy control were compared and the results are shown 
in the Table 1. Fasting glucose level was significantly different   
(p < 0.05).
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Inhibition of IL-6 production by cAMP in PBMNC from 
DM2  patients.  In  order  to  determine  whether  the  observed 
upregulation of ROS production in PBMNC from DM2 patients 
was associated with modulation in the production of pro- or 
anti-inflammatory cytokines, supernatants from PBMNC that 
had been cultured in the presence or absence of cAMP were 
assayed for IL-4, IL-6 and IFNγ. As can be seen from the results 
shown in Table 2, PBMNC from DM2 patients produced a sig-
nificantly (p < 0.05) higher amount of IL-6 (25.3 ± 2.88 pg/ml) 
as compared with cells from healthy subjects (3.0 ± 1.2 pg/ml)   
(Table 2 and Fig. 4). However, in the presence of cAMP, the 
secretion of IL-6 was significantly inhibited (45.7%) in DM2 
patients but remained unaltered in healthy subjects (Table 2). 
The levels of IL-4 and IFNγ produced by PBMNC from DM2 
patients  and  healthy  controls  were  not  significantly  different 
and were not modulated by the presence of cAMP (Table 2). 
Table 1. Characteristics of the studied groups
Values ± SE
Parameters Healthy subjects Type 2 diabetic patients
age (years) 51.4 ± 1.84 Ns 54.8 ± 1.63
Body mass index (kg/m2) 25.1 ± 2.16 Ns 28.13 ± 2.17
Fasting glucose (mg/dL) 87.0 ± 8.0 p < 0.05 170.0 ± 25.0 
abdominal circunference (cm) 88.8 ± 4.62 Ns 95.75 ± 5.06
hb (g/dL) 14.1 ± 0.39 Ns 13.26 ± 0.46
hba1C (%) ND. - 7.56 ± 0.42
Triglycerides (mg/dL) 111.3 ± 13.2 Ns 122.4 ± 17.42
Total cholesterol (mg/dL) 185.7 ± 6.83 Ns 181.2 ± 9.95
LDL Cholesterol (mg/dL) 109.4 ± 6.22 Ns 109.5 ± 6.38
hDL Cholesterol (mg/dL) 54.7 ± 4.17 Ns 47.3 ± 4.75
Creatinine (mg/Dl) 0.89 ± 0.05 Ns 1.0 ± 0.17
Urea (mg/dL) 31.16 ± 2.98 p < 0.05 47.16 ± 6.47
Ns: non significant (p > 0.05) Only fasting glucose level showed significant difference (p < 0.05) when healthy control and type 2 diabetic patients were 
compared.
Figure 2. effect of cyclic aMp (caMp) on ROs production in pBMNC 
from type 2 diabetic patients in comparison to healthy subjects. RLU/
min = Relative Light Units per minutes; pBMNC= peripheral blood 
mononuclear cells; The average were compared by student “t” test and 
p < 0.05 was considered as a significant difference.
the average ROS production by PBMNC derived from DM2   
patients (equivalent to 8.4 ± 1.2 expressed in RLU/min x 10-3; 
n = 15) was aproximately 1.6-times greater (p < 0.05) than by 
PBMNC from healthy individuals (5.0 ± 0.6 RLU/min x 10-3; 
n = 16) (Fig. 1). The ROS production expressed as RLU/min 
PBMNC and the ratios of ROS generation of ROS by PBMNC 
in the presence (E) and absence (C) of 10-5 M cAMP are shown 
in the Figures 2 and 3. In the Figure 5 is shown a typical curve 
of ROS production by PBMNC performed in the absence or in 
the presence of cAMP. The values of the E/C ratios were 1.75 for 
DM2, patients and 0.58 for healthy subjects (Fig. 3). It appears, 
therefore, that whilst cAMP induced a significant activation of 
ROS production by PBMNC from diabetic patients, its presence 
was inhibitory to ROS generation in healthy controls (Fig. 2).
Figure 1. Reactive Oxygen species (ROs) generation by peripheral 
blood mononuclear cells from type 2 diabetic patients—pBMNC = pe-
ripheral blood mononuclear cells; the values were compared by student 
“t” test; p < 0.05 were considered as significant; RLU/min = Relative 
Light Units per minute; pBs = phosphate buffered saline. ROs produc-
tion was greater in DM2 than in healthy control. DM2 = type 2 diabetic 
patients; pBMNC = peripheral blood mononuclear cells.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  319
by PBMNC from diabetic patients but it did not modulate IL-6   
production by PBMNC from healthy controls. This kind of con-
trol of interleukin synthesis has not been observed with either 
IL-4 or IFNγ. IL-6 has   previously been shown to modify insulin 
sensitivity,26 whilst an increase in the level of cAMP has been 
reported to upregulate both IL-1 beta and IL-6 transcripts.27
In spite of the observed increases in ROS and IL-6 generation 
by PBMNC derived from DM2 patients, no correlations were 
observed between ROS and IL-4, IL-6 or IFNγ in any of the 
experiments performed with cells from DM2 patients or from 
healthy individuals, either in the presence or absence of cAMP.
cAMP  enhances  the  activity  of  protein  kinase  A  (PKA)28 
which activates protein kinase C (PKC) and p38 MAPK lead-
ing to a NFκB activation with consequent induction of inducible 
nitric oxide synthase (iNOS) and IL-6.18
The activation of ROS production by cAMP in PBMNC from 
DM2 patients, and the concomitant downregulation of IL-6, may 
suggest a regulatory mechanism in the inflammatory process. We 
have previously suggested that cAMP modulates ROS produc-
tion in granulocytes from DM2 patients using a metabolic route 
PKA-independent, Epac/PKB-dependent.29 Izuora et al.10 have 
demonstrated that PGE2 levels did not correlate with the grade 
of retinopathy, and proposed that the elevation of PGE2 could 
be regarded as a marker of inflammation associated with micro-
vascular complications. Our present results suggest that elevated 
ROS production, in association with high levels of IL-6, could 
be considered as a typical profile of type 2 diabetes as well as 
suggestive of an active inflammatory response. It is proposed that 
the intracellular increase of cAMP, which might arise from the 
elevation of PGE2, could activate ROS production and simulta-
neous downregulation of IL-6. This may represent a novel type 
of regulatory mechanism of diabetic inflammation and reinforces 
previous findings.10
Statistical analyses revealed no correlations between ROS pro-
duction and levels of IL-4, IL-6 or IFNγ (Table 3).
Discussion
In this study we examined the reactivity of PBMNC from DM2 
patients in the presence and absence of a cAMP-elevating agent 
in comparison with cells from healthy controls. We observed 
an  altered  reactivity  for  ROS  and  IL-6  production  in  DM2   
patients,  whilst  IL-4  and  IFNγ  levels  were  insensitive  to  the 
hyperglycaemia of diabetes and to the intracellular elevation of 
cAMP.
Diabetes is believed to be an inflammatory disease in which 
the associated chronic hyperglycaemia is linked with an increase 
in ROS generation by PBMNC14 Results from the present study 
confirmed that the production of ROS in PBMNC from DM2 
patients is significantly greater than in cells from healthy indi-
viduals. It has been suggested that the rise in ROS production 
is associated with an increase of p47phox, a component of the 
NADPH-oxidase system.15 However, cytokine production may 
also be mediated by ROS,1 and in this context an increase in 
PGE2 has been reported in vascular complications of diabetes.10 
Since  PGE2  activates  adenyl  cyclase  to  form  cAMP,  a  func-
tional relationship between ROS, cAMP and cytokine secretion 
could be proposed. Mitogen-activated oritein kinases (MAPKs) 
includes three subgroups of MAPKs identified as extracellular 
signal-regulated kinase (ERK), p38 MAPK and cJun aminoter-
minal kinase (JNK).16,17 In J774 macrophages, the association 
between cAMP, NO and IL-6 was demonstrated,18 and ERK and 
p38 MAPK are involved in the upregulation of gene expression of 
inducible NO syntase (iNOS) and IL-6.19,20 Mitochondrial ROS 
and IL-6 activate AMP-activated protein kinses (AMPK) and the 
effect of IL-6 depends on cAMP.20,21
We have previously reported that cAMP increases ROS pro-
duction in granulocytes from patients with diabetes types 1 and 
2 via a PKA-independent signalling pathway.23 In the present 
study, we were able to demonstrate a similar effect of cAMP 
on  PBMNC  from  DM2  patients,  although  cAMP  inhibited 
ROS generation in PBMNC from healthy controls (Figs. 2, 3 
and 5). It may thus be hypothesised that the hyperglycaemia of   
diabetes  induces  an  adaptation  in  the  metabolic  response  of   
diabetic patients.
In order to investigate the possible association between ROS 
production and the release of cytokines, we evaluated the pro-
duction  of  the  anti-inflammatory  cytokine  IL-4  and  the  two 
pro-inflammatory cytokines IL-6 and IFNγ by PBMNC in the 
presence and absence of a cAMP-elevating agent. In these experi-
ments, the levels of IL-4 and IFNγ were similar in PBMNC 
derived from DM2 patients and from healthy controls, both in 
the presence and absence of cAMP (Table 2, Fig. 4). The results 
relating to IL-4 are in agreement with those reported from pre-
vious studies.24,25 More significantly, however, is that the pres-
ent study revealed an increase in both ROS and IL-6 production 
by PBMNC derived from DM2 patients as compared with cells 
from healthy individuals (Table 2; Fig. 4). Furthermore, intrac-
ellular elevation of cAMP induced an inhibition of IL-6 secretion 
Figure 3. The effect of caMp on ROs production in pBMNC from 
DM2 patients and from healthy subjects. The results are expressed 
in the form of the ratio e/C for individual subjects, where e refers to 
cells cultured in the presence of caMp (experiment) and C refers to 
cells cultured in the absence of the additive (Control). e/C = [RLU/min 
produced by pBMNC in the presence of caMp]/[RLU/min produced by 
pBMNC in the absence of caMp]. RLU/min = Relative Light Units per 
minutes; pBMNC= peripheral blood mononuclear cells.320  Oxidative Medicine and Cellular Longevity  Volume 2 Issue 5
Preparation of peripheral blood mononuclear cells. PBMNC 
were purified from 10.0 ml of heparinised venous blood using the 
Ficoll-Hypaque gradient method as described previously.30 In the 
present study, three different densities of Ficoll-Hypaque gradi-
ent were employed and three interfaces were formed following   
centrifugation.  The  first  (upper)  interface  was  rich  in  mono-
nuclear  cells  and  depleted  in  granulocytes,  whilst  the  second 
interface  was  neutrophil-rich  (100%),  and  the  third  interface 
was composed of neutrophils (±95%) and eosinophils (±5%).   
The cell fraction depleted in granulocytes was employed in the 
experiments described herein. The viability of cells in all samples 
was of >95% as determined by the Trypan blue exclusion test.
Quantifiation of ROS in peripheral blood mononuclear cells 
(PBMNC). The generation of ROS was measured quantitatively 
by chemiluminescence assay using a Magic Lite luminometer, 
Table 2. The modulation by caMp of cytokine production in pBMNC from type 2 diabetic patients and healthy individuals
Level of cytokines (pg/ml)a
PBMNC + cAMP PBMNC
Cytokines Healthy subjects DM2 patients Healthy subjects DM2 patients
IL-6 3.5 ± 1.26 p < 0.05b 14.1 ± 3.04 3.0 ± 1.2 p < 0.05b 25.3 ± 2.88
INFγ 6.64 ± 0.41 nsb 8.75 ± 1.18 6.39 ± 0.39 nsb 7.02 ± 0.51
IL-4 232 ± 1.63 nsb 231.2 ± 2.8 239.4 ± 7.5   nsb  230.6 ± 2.9
aMean values ± sD (n = 9); Cytokines quantification was performed by eLIsa using supernatant of cultured pBMNC (peripheral blood mononuclear 
cells). bMean values between groups were compared using student t-tests; p < 0.05 was considered significant; ns, not significant. IFNγ, IL-6 and IL-4 
refer to gamma interferon, interleukin 6 and interleukin 4, respectively. 
Taken together, our results provide evidences that cAMP may 
play a prominent role in IL-6 modulation in PBMNC from DM2 
patients and, consequently, in the pathogenesis of diabetes.
Materials and Methods
Details of the project were presented to and approved by the 
Ethical Committee of the Hospital Santa Casa de Belo Horizonte 
(Belo Horizonte—MG, Brazil). Appropriate informed consent 
was obtained from all participants prior to the commencement 
of the study.
Subjects. Patients suffering from DM2 (diagnosed according 
to the criteria of the American Diabetes Association) and healthy 
volunteers, all within the age range of 30–75 years, were recruited 
from  the  endocrinology  service  of  the  Santa  Casa  Hospital.   
Each volunteer was submitted to a detailed physical examina-
tion, together with an evaluation of relevant medical history and 
laboratory data, before being subjected to the study. The levels of 
fasting plasma glucose were determined to be 170 ± 25 and 87 ± 
8.0 mg/dl, respectively, for DM2 patients and healthy controls 
(Table 1).
Figure 4. Quantification of IL-6 in supernatant of cultured PBMNC. 
pBMNC (peripheral blood mononuclear cells) were cultured in RpMI-
1640 and the culture supernatant, cell-free, was assayed for interleukin 
6 (IL-6). Comparison of IL-6 in supernatant of pBMNC from DM2 and 
healthy control. peripheral blood mononuclear cells (pBMNC) were 
cultured in RpMI-16-40 for 48 h at 37°C. The supernatant cell-free was 
used for quantification of inteleukin 6 (IL-6) in an ELISA commercial kit. 
The values were compared by student “t” test and the difference be-
tween IL-6 from healthy control and from type diabetic patients (DM2) 
was significant.
Figure 5. (a and B) represent typical curves of kinetics studies on 
reactivie oxygen species (ROs) generation by peripheral blood mono-
nuclear cells (pBMNC) either from healthy control (a) or from type 
2 diabetic patients (B) in the presence or in the absence of cyclic aMp 
(caMp).www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  321
cAMP-elevating agent dibutyryl cAMP (dbcAMP; Sigma, St. 
Louis, MO, USA) and the chemiluminescence was recorded for 
an additional 30 min.
Determination of cytokines in the supernatant of PBMNC. 
Aliquots (200 μl) of a suspension of PBMNC (1 x 106/ml) in 
RPMI-1640 medium were incubated in the presence or absence 
of dbcAMP (100 μL of a 10-5 M solution) for 48 h at 37°C under 
5% CO2. Following incubation, the cells were centrifuged and 
the  supernatant  collected.  The  concentrations  of  IL-4,  IL-6 
and IFNγ were measured by sandwich ELISA using kits sup-
plied by R&D Systems (Minneapolis, MN, USA) and Assay 
Designs (Ann Arbor, MI, USA). Plates were read at 450 nm on 
an automated ELISA plate reader, and the levels of cytokines 
were determined by reference to standard curves constructed 
using recombinant IL-4, IL-6 and IFNγ.
Statistical analyses. Data were expressed in terms of mean 
values ± standard deviations. Comparisons of data between 
groups were performed with the aid of Origin 6.0 (Microcal 
Software Inc., Northampton, MA, USA) by using unpaired 
Student t-tests, analysis of variance (ANOVA) and Pearce cor-
relation analyses. In each case a p value <0.05 was considered 
to be significant.
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(Ciba Corning Co., Medfield, MA, USA). An aliquot (100 μl) 
of phosphate buffer saline (PBS) containing mononuclear cells   
(1  x  106),  previously  washed  in  PBS,  was  transferred  to  an 
unsealed luminescence tube together with 200 μl of luminol 
(dissolved in 0.4 M dimethyl sulphoxide). The final volume 
was adjusted to 700 μl with PBS (pH 7.3). Chemiluminescence 
[expressed  in  relative  light  units  (RLU)/min]  was  recorded 
over a 30 min period in a control tube. In another tube, ROS 
production was measured using the same reagents as those in 
control tube plus a 100 μl aliquot of a 10-5 M solution of the 
Table 3. Correlation between reactive oxygen species (ROs) produc-
tion and cytokines secretions
ROS production—RLU/min
Cytokines Absence of cAMP Presence of cAMP
ND DM2 ND DM2
r  r   r r
IL-6 -0.039 0.130 -0.442 -0.340
IFN 0.373 -0.088 -0.138 -0.416
IL-4 0.025 0. 037 -0.072 0.439
r = represent the coefficient of correlation (pearson). The secretion of 
cytokines were evaluated in the presence and in the absence of cyclic 
aMp. No correlation between ROs production and cytokine releasing 
was observed. DM2 = Type 2 diabetic patients; ND = healthy control.
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